American Society for Investigative Pathology, Rockville, Maryland.
Dreyfus Consulting, LLC, Silver Spring, Maryland.
Am J Pathol. 2020 May;190(5):918-933. doi: 10.1016/j.ajpath.2020.01.014. Epub 2020 Mar 19.
The recent movement toward returning individual research results to study subjects/participants generates ethical and legal challenges for laboratories performing research on human biospecimens. The concept of an individual's interest in knowing the results of testing on their tissue is pitted against individual and systemic risks and an established legal framework regulating the performance of laboratory testing for medical care purposes. This article discusses the rationale for returning individual research results to subjects, the potential risks associated with returning these results, and the legal framework in the United States that governs testing of identifiable human biospecimens. On the basis of these considerations, this article provides recommendations for investigators to consider when planning and executing human biospecimen research, with the objective of appropriately balancing the interests of research subjects, the need for ensuring integrity of the research process, and compliance with US laws and regulations.
近年来,将个体研究结果返还给研究对象/参与者的趋势给进行人类生物样本研究的实验室带来了伦理和法律挑战。个体了解其组织检测结果的利益的概念与个体和系统风险以及为医疗目的进行实验室检测而制定的现有法律框架相冲突。本文讨论了将个体研究结果返还给对象的基本原理、返还这些结果所涉及的潜在风险,以及美国管理用于识别人类生物样本检测的法律框架。基于这些考虑,本文为研究人员在规划和执行人类生物样本研究时提供了一些建议,旨在平衡研究对象的利益、确保研究过程的完整性以及遵守美国法律法规的需求。